/
Infectious Disease
Respiratory Syncytial Virus
10
Pipeline Programs↗
17
Active Trials↗
14
Companies Involved↗
Respiratory Syncytial Virus is an early-stage landscape with 10 programs across 14 companies. The most active players are Moderna, Sanofi, Suzhou Abogen Biosciences Co., Ltd.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 31
Approved
No programs
Analysis
Modality Breakdown
4programs
RNA therapy250%
Vaccine250%
Modality classified for 60% of 10 pipeline programs.
Analysis
Trial Status
59
clinical trials
Completed35 · 59%
Active, not recruiting10 · 17%
Terminated6 · 10%
Recruiting5 · 8%
Not yet recruiting2 · 3%
Unknown status1 · 2%
Clinical Trials
Trial Activity
59 trials
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)